

-25-

What is Claimed:

1. A method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the
5 subject an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject.
- 10 2. The method of claim 1, wherein the form of multiple sclerosis is relapsing-remitting multiple sclerosis.
3. The method of claim 1 or 2, wherein the subject is a human being.
- 15 4. The method of any one of claims 1-3, wherein each of the amount of glatiramer acetate when taken alone, and the amount of mitoxantrone when taken alone is effective to alleviate the symptom of the form of multiple sclerosis.
- 20 5. The method of any one of claims 1-3, wherein either the amount of glatiramer acetate when taken alone, the amount of mitoxantrone when taken alone or each such amount when taken alone is not effective to alleviate the symptom of the form of
25 multiple sclerosis.
6. The method of any one of claims 1-5, wherein the symptom is the frequency of relapses, the frequency of clinical exacerbation, or the accumulation of physical disability.
- 30 7. The method of any one of claims 1-6, wherein the amount of glatiramer acetate is in the range from 10 to 600 mg/week.
8. The method of claim 7, wherein the amount of glatiramer
35 acetate is 300 mg/week.

-26-

9. The method of any one of claims 1-6, wherein the amount of glatiramer acetate is in the range from 50 to 150 mg/day.

5 10. The method of claim 9, wherein the amount of glatiramer acetate is 100 mg/day.

11. The method of any one of claims 1-6, wherein the amount of glatiramer acetate is in the range from 10 to 80 mg/day.

10 12. The method of claim 11, wherein the amount of glatiramer acetate is 20 mg/day.

13. The method of any one of claims 1-12, wherein the periodic administration of glatiramer acetate is effected daily.

15 14. The method of any one of claims 1-12, wherein the periodic administration of glatiramer acetate is effected twice daily at one half the amount.

20 15. The method of any one of claims 1-12, wherein the periodic administration of glatiramer acetate is effected once every 5 to 9 days.

25 16. The method of any one of claims 1-15, wherein the administration of the glatiramer acetate substantially precedes the administration of the mitoxantrone.

30 17. The method of any one of claims 1-15, wherein the administration of the mitoxantrone substantially precedes the administration of the glatiramer acetate.

35 18. The method of any one of claims 1-17, wherein the administration of the glatiramer acetate is effected subcutaneously, intraperitoneally, intravenously, intramuscularly, intraocularly or orally and the administration

-27-

of the mitoxantrone is effected intravenously.

19. The method of claim 18, wherein the administration of the
glatiramer acetate is effected subcutaneously and the
administration of the mitoxantrone is effected intravenously.

20. A pharmaceutical composition comprising an amount of
glatiramer acetate and an amount of mitoxantrone, wherein the
amounts when taken together are effective to alleviate a symptom
of a form of multiple sclerosis in a subject.

21. The pharmaceutical composition of claim 20, wherein each of
the amount of glatiramer acetate when taken alone and the amount
of mitoxantrone when taken alone is effective to alleviate the
symptom of multiple sclerosis.

22. The pharmaceutical composition of claim 20, wherein either
of the amount of glatiramer acetate when taken alone, or the
amount of mitoxantrone when taken alone or each such amount when
taken alone is not effective to alleviate the symptom of
multiple sclerosis.

23. A package comprising

- i) a first pharmaceutical composition comprising an
amount of glatiramer acetate and a
pharmaceutically acceptable carrier;
- ii) a second pharmaceutical composition comprising an
amount of mitoxantrone and a pharmaceutically
acceptable carrier; and
- iii) instructions for use of the first and second
pharmaceutical compositions together to alleviate
a symptom of a form of multiple sclerosis in a
subject.

24. The package of claim 23, wherein the amount of glatiramer

-28-

acetate is 300 mg.

25. The package of claim 23, wherein the amount of glatiramer acetate is 20 mg.